menu
    • menu
    [{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Assia Chemical Industries Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assia Chemical Industries Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Assia Chemical Industries Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Agreement","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Taiwan Liposome Company \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Endo International"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Taiwan Liposome Company \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Inapplicable"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"TLC BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TLC BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TLC BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Shionogi"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JZP-258","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Almac Group","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Almac Group \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Almac Group \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Alliance Global Partners"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Rho","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Rho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Rho \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Rho \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Condoliase","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Seikagaku \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Engineered Gingival Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Norgine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"FSHD Society","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ FSHD Society","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ FSHD Society"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Losmapimod","moa":"MAPK\/p38-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Biosplice","sponsor":"Samil Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Samil Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Samil Pharmaceutical"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Clonidine","moa":"||Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Bell Potter Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Bell Potter Securities","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Bell Potter Securities"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Diclofenac Conjugated Sodium Hyaluronate","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seikagaku \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Eisai"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TissueGene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Kolon TissueGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon TissueGene \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Samumed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samumed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Samumed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samumed \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"||Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TissueGene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Kolon TissueGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon TissueGene \/ Inapplicable"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"||CD44","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Anika Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Clonidine","moa":"||Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"HUNGARY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gedeon Richter \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ US Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ US Food & Drug Administration"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Endo International"},{"orgOrder":0,"company":"Alvotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoNex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Inapplicable"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoNex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Inapplicable"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lupin Ltd \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ DKSH"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Mabxience","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Mabxience","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Mabxience"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Epidural Injection","sponsorNew":"Scilex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Epidural Injection","sponsorNew":"Scilex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Pre-Filled Injection","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Pre-Filled Injection","sponsorNew":"Scilex Pharmaceuticals \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp I","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2022","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Pre-Filled Injection","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I"},{"orgOrder":0,"company":"HintMD","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"HintMD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HintMD \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"HintMD \/ Revance Therapeutics"},{"orgOrder":0,"company":"CuraTeQ Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANKL","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"CuraTeQ Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CuraTeQ Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CuraTeQ Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANKL","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apimeds Pharmaceuticals","sponsor":"D. Boral Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Public Offering","leadProduct":"Honeybee Toxin","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Apimeds Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intradermal Injection","sponsorNew":"Apimeds Pharmaceuticals \/ D. Boral Capital","highestDevelopmentStatusID":"10","companyTruncated":"Apimeds Pharmaceuticals \/ D. Boral Capital"},{"orgOrder":0,"company":"Apimeds Pharmaceuticals","sponsor":"D. Boral Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Public Offering","leadProduct":"Honeybee Toxin","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Apimeds Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intradermal Injection","sponsorNew":"Apimeds Pharmaceuticals \/ D. Boral Capital","highestDevelopmentStatusID":"10","companyTruncated":"Apimeds Pharmaceuticals \/ D. Boral Capital"}]

    Find Musculoskeletal Drugs in Phase III Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering

                            Details : The net proceeds from the offering will be used to fund the clinical development of Apitoxin, which is being evaluated for the treatment of Knee Osteoarthritis.

                            Product Name : Apitoxin

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            May 12, 2025

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

                            Details : The net proceeds from the offering will be used to fund the clinical development of Apitoxin, which is being evaluated for the treatment of Knee Osteoarthritis.

                            Product Name : Apitoxin

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            May 08, 2025

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biocon Biologics

                            India arrow
                            American Thoracic Society
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biocon Biosimilars Vevzuo and Denosumab BBL Receive Positive CHMP Opinion

                            Details : Vevzuo (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia. It is a RANK ligand inhibitor, which is indicated for postmenopausal osteoporosis.

                            Product Name : Vevzuo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 28, 2025

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CuraTeQ Biologics

                            India arrow
                            American Thoracic Society
                            Not Confirmed

                            CuraTeQ Biologics

                            India arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CuraTeQ Biologics Completes Phase 1 Pharmacokinetics Study of Biosimilar Denosumab

                            Details : BP16 (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia. It is a RANK ligand inhibitor, which is being evaluated for postmenopausal osteoporosis.

                            Product Name : BP16

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 09, 2025

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alvotech

                            Iceland arrow
                            American Thoracic Society
                            Not Confirmed

                            Alvotech

                            Iceland arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Dr. Reddy's Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alvotech-Dr. Reddy’s FDA Filing Accepted for AVT03 Biosimilar to Prolia/Xgeva

                            Details : AVT03 (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is being evaluated in phase 1 trials for bone loss in adult men.

                            Product Name : AVT03

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Dr. Reddy's Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Mabxience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

                            Details : MB09 (denosumab), referencing Xgeva, is being evaluated for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone)

                            Product Name : MB09

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Mabxience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GlycoNex

                            Taiwan arrow
                            American Thoracic Society
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GlycoNex Announces Licensing Agreement for SPD8 Biosimilar

                            Details : Under the terms of agreement, the licensee will obtain rights to develop, secure regulatory approval for, and commercialize SPD8 (Denosumab) biosimilar to Prolia for the treatment of osteoporosis.

                            Product Name : SPD8

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tonix Pharmaceuticals Holding Corp

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Tonix Pharmaceuticals Holding Corp

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclobenzaprine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tonix Announces August 2025 PDUFA Date for TNX-102 SL Fibromyalgia Decision

                            Details : TNX-102 SL is a centrally acting, non-opioid bedtime investigational drug, designed for chronic use. It is being evaluated for the treatment of Fibromyalgia.

                            Product Name : Tonmya

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 23, 2024

                            Lead Product(s) : Cyclobenzaprine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tonix Pharmaceuticals Holding Corp

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Tonix Pharmaceuticals Holding Corp

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclobenzaprine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tonix Receives NDA Acceptance for TNX-102 SL To Treat Fibromyalgia

                            Details : TNX-102 SL is a centrally acting, non-opioid bedtime investigational drug, designed for chronic use. It is being evaluated for the treatment of Fibromyalgia.

                            Product Name : Tonmya

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Cyclobenzaprine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GlycoNex

                            Taiwan arrow
                            American Thoracic Society
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar

                            Details : SPD8 (denosumab) is a biosimilar of Prolia and Xgeva, designed for use in postmenopausal women with osteoporosis. This medication is administered subcutaneously and functions as a RANKL inhibitor.

                            Product Name : SPD8

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth